otcaddict, I was not referring to remdesivir study, was

otcaddict, I was not referring to remdesivir study, was referring to remestemcel-L study by Mesoblast.

The context was NP touting leronlimab is only trial with mortality as PE.

In NP's defense, however, he does have a few CYA moments when he says "that I'm aware of" or "we're the only one, (mumble, mumble) or 2 or 3."

https://www.clinicaltrials.gov/ct2/show/NCT04371393